Cobomarsen (MRG-106) is an oligonucleotide inhibitor targeting miR-155. This compound effectively suppresses various gene pathways involved in cell survival, such as JAK/STAT, MAPK/ERK, and PI3K/AKT. Cobomarsen is particularly valuable in the study of B-cell lymphoma.

Cobomarsen (10 μM; 48-96 h) reduces cell proliferation and induces apoptosis in U2932, OCI-LY3, and RCK8 cells[2]. Cobomarsen (10 μM; 72 h) significantly increases the expression of the four direct targets in the cell lines that overexpress miR-155[1]. Cobomarsen (10 μM; 12 days) reduces cellular proliferation and induces apoptosis in MF and HTLV-1+ CTCL cells[1]. Cobomarsen (10-50 μM; 7 days) reduces phosphorylation of the downstream signalling proteins AKT, ERK1/2, and STAT-3 in primary human activated T cells or MF cell lines[1]. Cell Proliferation Assay[2]Cell Line: U2932, OCI-LY3 and RCK8 cells Concentration: 10 μM Incubation Time: 48, 72, 96 hours Result: Concentration-dependently inhibited cell phosphorylation. Apoptosis Analysis[2]Cell Line: U2932, OCI-LY3 and RCK8 cells Concentration: 10 μM Incubation Time: 96 hours Result: Triggered a significant induction of late apoptosis in all cell lines.

Cobomarsen (1 mg/kg; i.v. on days 0, 2, 4, and 7) inhibits tumor growth in mice carrying U2932 cells xenografts[2]. Animal Model: Five-to-six weeks old female NSG mice injected with U2932 cells Dosage: 1 mg/kg Administration: I.v. on days 0, 2, 4, and 7 Result: Reduced tumor growth most significantly at day 7 and day 10.